CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Inclusion Criteria: * Male and female subjects with CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or refractory to 2 multidrug regimens and/or anti-CD30 antibody treatment. * Newly diagnosed CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma patients who are unable to receive or complete standard chemotherapy. * Karnofsky or Lansky score greater than 60%. * Expected survival\>12 weeks. * Creatinine\<2.5mg/dl. * ALT (alanine aminotransferase)/AST (aspartate aminotransferase)\<3 fold normal. * Bilirubin\<2.5mg/dl. * Pulse oximetry of \>90% on room air. * Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of expected corrected for hemoglobin. * Available autologous T cells with 10% or more expression of CD30 CAR determined by flow-cytometry. * Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form. Exclusion Criteria: * Active infection such as hepatitis B or C. * Receive anti-CD30 antibody-based therapy within recent 6 weeks. * Current use of systemic corticosteroids. * Pregnant or lactating. * Confirmed tumor in pulmonary and archenteric tissues.